Santhera Pharmaceuticals Holding AG 0QN1
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- CHF 0.00 / CHF 0.00
- Market Cap
- CHF 111.18 Mil
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 16.30
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives most of its revenue from the European Union.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 51
- Website
- https://www.santhera.com
Comparables
Valuation
|
Metric
|
0QN1
|
MLTX
|
VECT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 5.20 | 4.95 |
Price/Sales | 16.30 | — | 27.19 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
0QN1
|
MLTX
|
VECT
|
|---|---|---|---|
Quick Ratio | 0.05 | 61.56 | 9.01 |
Current Ratio | 0.14 | 62.13 | 9.14 |
Interest Coverage | −2.27 | — | −41.28 |
Quick Ratio
0QN1
MLTX
VECT
Profitability
|
Metric
|
0QN1
|
MLTX
|
VECT
|
|---|---|---|---|
Return on Assets (Normalized) | −74.88% | −9.28% | −37.23% |
Return on Equity (Normalized) | — | −10.06% | −44.82% |
Return on Invested Capital (Normalized) | −362.57% | −9.46% | −42.88% |
Return on Assets
0QN1
MLTX
VECT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Yvkjlbjj | Tpcr | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zpfdcmgd | Qjbslq | $109.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hwtpnptv | Llmcd | $105.3 Bil | |
MRNA
| Moderna Inc | Gdkpcpf | Fqjs | $47.0 Bil | |
ARGX
| argenx SE ADR | Nckptxz | Tdpts | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Fzgtdzgm | Cncc | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fscwztlg | Lhzhr | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kpnllmqd | Nbktv | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gvjdsyyzk | Qgjpjz | $12.7 Bil | |
INCY
| Incyte Corp | Qpyrzkn | Ccymtpf | $12.0 Bil |